

Dr Chrys Pulle
Prof Chris Rowe
A/Prof Michael
Woodward
Prof Sue Kurrle
Prof Henry Brodaty

Case Presentation



Case Study Mr. MC



- 78 yr old male retired Doctor
- Married to professional
- Lives in regional town
- 2 yrs STM impairment
- Increasing anxiety, low grade depressive symptoms
- Past Medical History – IHD, Familial Hypercholesterolemia, GORD, BCC, Irritable Bowel Syndrome
- Family Hx of Alzheimer’s Disease (mother)
- No history of anxiety/ Depression
- Perfectionist traits
- Meds- Aricept 5mg, Memantine 10mg, Micardis 40mg, Rosuvastatin 10mg, Ezetimibe 10 mg
- MMSE 26/30 on referral for Clinical Trial

Case Study Mr. MC


Investigations


- MRI
- FDG PET
- Plasma Biomarkers
- CSF Biomarkers
- APOE4 Genotyping

MRI Mr. MC




PET 18F Florbetaben Mr. MC






Trial Screening Neuroimaging

MRI




PET




Trial Screening Florbetaben (Neuroceq) PET Imaging


Figure 1 Axial view of negative (top row) and positive (bottom row) Neuroceq PET scans



Trial Screening Amyloid PET Florbetaben (Neuraceq)



- MRI



- PET

- Fused PET/MRI

Clinical Trials

- Which trial is suitable for Mr. MC ?
- Duration?
- Frequency of Visits?
- Carer Burden?
- How do we broaden Clinical trials for CALD/ Indigenous participants?

Mr. MC


History of Progression

- AOE 4 Positive
- Qualified for Anti Amyloid Trial 18/12
- Continued progressive cognitive decline
- 9 months decided to withdraw
- What next?
- Increasing behavioural symptoms
- Carer burden now contemplating residential care
- Moderate to Severe Dementia
MMSE 15/30

Discussion Topics

- Neuroimaging/ Clinical Trial Suitability
- Management Strategies & reduce carer burden
- Anxiety & Depression, family issues and post-diagnostic issues

Thankyou



Questions ?

DTAus - Alzheimer's beyond COVID-19

Summary



- **How has COVID affected dementia research?** *A/Prof. Michael Woodward*
- **Alzheimer's Dementia Trials Update 2021** *Dr. Roger Clarnette*
- **Choosing the correct trial - Are AD Trial Protocols fit for purpose? Why do our patients screen fail?**
A/Prof. Michael Woodward
- **ADNet & Neuro Imaging & Other Biomarkers** *Prof. Chris Rowe*
- **Vascular Dementia & LATE TDP 43 mechanisms in dementia** *Prof. Glenda Halliday*
- **PTSD & Dementia - Is there a link and do we need more trials?** *Prof. Philip Morris*
- **BPSD & Research - What have we learned & do we need new trials?** *Prof. Henry Brodaty*
- **Dementia Pathways - Has research improved management?** *Prof. Sue Kurrle*

Panel Discussion - The Patient Journey

Prof. Sue Kurrle, Prof. Henry Brodaty & A/Prof. Michael Woodward

Sponsors



Neuroscience Trials Australia
(NTA)



Australian
Dementia Network
REGISTRY. CLINICS. TRIALS.